Role of endogenous ET-1 in the regulation of myocardial blood flow in lean and obese humans

Obesity

Volumn 18, Issue 1, 2010, Pages 63-70

  Mather, Kieren J ^a   Lteif, Amale A ^a   Veeneman, Emily ^a   Fain, Richard ^a   Giger, Susan ^a   Perry, Kevin ^a   Hutchins, Gary D ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLO(TRP ASP PRO VAL LEU); CYCLO(TRP-ASP-PRO-VAL-LEU); CYCLOPEPTIDE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BODY MASS; CORONARY ARTERY BLOOD FLOW; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HEMODYNAMICS; HUMAN; MALE; METABOLISM; OBESITY; PATHOPHYSIOLOGY; PATIENT SELECTION; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; REGRESSION ANALYSIS;

ADULT; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; BODY MASS INDEX; CORONARY CIRCULATION; ENDOTHELIN-1; FEMALE; HEMODYNAMICS; HUMANS; MALE; OBESITY; PATIENT SELECTION; PEPTIDES, CYCLIC; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, ENDOTHELIN A; REGRESSION ANALYSIS;

EID: 73949095443     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2009.196     Document Type: Article

References (61)

1. Mather KJ, Mirzamohammadi B, Lteif A, Steinberg HO, Baron AD. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes 2002;51:3517-3523.
2. Mather KJ, Lteif A, Steinberg HO, Baron AD. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes 2004;53:2060-2066.
3. Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 2002;106:1783-1787.
4. Cardillo C, Campia U, Iantorno M, Panza JA. Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension 2004;43:36-40.
5. Pitkänen O P, Nuutila P, Raitakari OT et al. Coronary flow reserve is reduced in young men with IDDM. Diabetes 1998;47:248-254.
6. Sundell J, Janatuinen T, Rönnemaa T et al. Diabetic background retinopathy is associated with impaired coronary vasoreactivity in people with Type 1 diabetes. Diabetologia 2004;47:725-731.
7. Momose M, Abletshauser C, Neverve J et al. Dysregulation of coronary microvascular reactivity in asymptomatic patients with type 2 diabetes mellitus. Eur J Nucl Med Mol Imaging 2002;29:1675-1679.
8. Nahser PJ, Brown RE, Oskarsson H, Winniford MD, Rossen JD. Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation 1995;91:635-640.
9. Yokoyama I, Momomura S, Ohtake T et al. Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1997;30:1472-1477.
10. Dagres N, Saller B, Haude M et al. Insulin sensitivity and coronary vasoreactivity: insulin sensitivity relates to adenosine-stimulated coronary flow response in human subjects. Clin Endocrinol (Oxf) 2004;61:724-731.
11. McGowan FX, Davis PJ, del Nido PJ et al. Endothelium-dependent regulation of coronary tone in the neonatal pig. Anesth Analg 1994;79: 1094-1101.
12. Quyyumi AA, Dakak N, Andrews NP et al. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation 1995; 92:320-326.
13. Duffy SJ, Castle S F, Harper RW, Meredith I T. Contribution of vasodilator prostanoids and nitric oxide to resting flow, metabolic vasodilation, and flow-mediated dilation in human coronary circulation. Circulation 1999;100: 1951-1957.
14. Tune JD, Richmond KN, Gorman MW, Feigl EO. Role of nitric oxide and adenosine in control of coronary blood flow in exercising dogs. Circulation 2000;101:2942-2948.
15. Altman JD, Kinn J, Duncker DJ, Bache RJ. Effect of inhibition of nitric oxide formation on coronary blood flow during exercise in the dog. Cardiovasc Res 1994;28:119-124.
16. Bernstein RD, Ochoa F Y, Xu X et al. Function and production of nitric oxide in the coronary circulation of the conscious dog during exercise. Circ Res 1996;79:840-848. (Pubitemid 26317833)
17. Ishibashi Y, Duncker DJ, Zhang J, Bache RJ. ATP-sensitive K+ channels, adenosine, and nitric oxide-mediated mechanisms account for coronary vasodilation during exercise. Circ Res 1998;82:346-359.
18. Recchia FA, McConnell PI, Loke KE et al. Nitric oxide controls cardiac substrate utilization in the conscious dog. Cardiovasc Res 1999;44: 325-332.
19. Shen W, Ochoa M, Xu X, Wang J, Hintze TH. Role of EDRF/NO in parasympathetic coronary vasodilation following carotid chemoreflex activation in conscious dogs. Am J Physiol 1994;267:H605-H613.
20. Farouque HM, Worthley SG, Meredith IT, Skyrme-Jones RA, Zhang MJ. Effect of ATP-sensitive potassium channel inhibition on resting coronary vascular responses in humans. Circ Res 2002;90:231-236.
21. de Beer VJ, Sorop O, Pijnappels DA et al. Integrative control of coronary resistance vessel tone by endothelin and angiotensin II is altered in swine with a recent myocardial infarction. Am J Physiol Heart Circ Physiol 2008;294:H2069-H2077.
22. Merkus D, Duncker DJ, Chilian WM. Metabolic regulation of coronary vascular tone: role of endothelin-1. Am J Physiol Heart Circ Physiol 2002; 283:H1915-H1921.
23. Brunner F, Brás-Silva C, Cerdeira AS, Leite-Moreira AF. Cardiovascular endothelins: essential regulators of cardiovascular homeostasis. Pharmacol Ther 2006;111:508-531.
24. Merkus D, Sorop O, Houweling B et al. NO and prostanoids blunt endothelin-mediated coronary vasoconstrictor influence in exercising swine. Am J Physiol Heart Circ Physiol 2006;291:H2075-H2081.
25. Gorman MW, Farias M, Richmond KN, Tune JD, Feigl EO. Role of endothelin in alpha-adrenoceptor coronary vasoconstriction. Am J Physiol Heart Circ Physiol 2005;288:H1937-H1942.
26. Kuruvilla L, Kartha CC. Molecular mechanisms in endothelial regulation of cardiac function. Mol Cell Biochem 2003;253:113-123.
27. Shah AM, Grocott-Mason RM, Pepper CB et al. The cardiac endothelium: cardioactive mediators. Prog Cardiovasc Dis 1996;39:263-284.
28. Duncker DJ, Merkus D. Exercise hyperaemia in the heart: the search for the dilator mechanism. J Physiol (Lond) 2007;583:847-854.
29. Knudson JD, Dincer UD, Bratz IN et al. Mechanisms of coronary dysfunction in obesity and insulin resistance. Microcirculation 2007;14:317-338.
30. MacCarthy PA, Pegge NC, Prendergast BD, Shah AM, Groves PH. The physiological role of endogenous endothelin in the regulation of human coronary vasomotor tone. J Am Coll Cardiol 2001;37:137-143.
31. Halcox J P, Nour KR, Zalos G, Quyyumi AA. Endogenous endothelin in human coronary vascular function: differential contribution of endothelin receptor types A and B. Hypertension 2007;49:1134-1141.
32. Halcox J P, Nour KR, Zalos G, Quyyumi AA. Coronary vasodilation and improvement in endothelial dysfunction with endothelin ET(A) receptor blockade. Circ Res 2001;89:969-976.
33. Knudson JD, Rogers PA, Dincer UD et al. Coronary vasomotor reactivity to endothelin-1 in the prediabetic metabolic syndrome. Microcirculation 2006;13:209-218.
34. Wölkart G, Pang X, Stessel H, Kirchengast M, Brunner F. Chronic endothelin-A receptor antagonism is as protective as angiotensin converting enzyme inhibition against cardiac dysfunction in diabetic rats. Br J Pharmacol 2007;151:1187-1197.
35. Paradisi G, Smith L, Burtner C et al. Dual energy X-ray absorptiometry assessment of fat mass distribution and its association with the insulin resistance syndrome. Diabetes Care 1999;22:1310-1317.
36. Raylman RR, Caraher JM, Hutchins GD. Sampling requirements for dynamic cardiac PET studies using image-derived input functions. J Nucl Med 1993; 34:440-447.
37. Muzik O, Beanlands RS, Hutchins GD et al. Validation of nitrogen-13-ammonia tracer kinetic model for quantification of myocardial blood flow using PET. J Nucl Med 1993;34:83-91.
38. Hutchins GD, Schwaiger M, Rosenspire KC et al. Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol 1990;15: 1032-1042.
39. Sawada S, Muzik O, Beanlands RS et al. Interobserver and interstudy variability of myocardial blood flow and flow-reserve measurements with nitrogen 13 ammonia-labeled positron emission tomography. J Nucl Cardiol 1995;2:413-422.
40. Meyer C, Schwaiger M. Myocardial blood flow and glucose metabolism in diabetes mellitus. Am J Cardiol 1997;80:94A-101A.
41. Kiviniemi TO, Snapir A, Saraste M et al. Determinants of coronary flow velocity reserve in healthy young men. Am J Physiol Heart Circ Physiol 2006; 291:H564-H569.
42. Lteif A, Vaishnava P, Baron AD, Mather KJ. Endothelin limits insulin action in obese/insulin-resistant humans. Diabetes 2007;56:728-734.
43. Yoon N, Lteif A, Han K, Mather K. Endothelin contributes differently to peripheral vascular tone and blood pressure in human obesity and diabetes. J Am Soc Hypertens 2008;6:44.
44. Resink TJ, Scott-Burden T, Boulanger C, Weber E, Bühler FR. Internalization of endothelin by cultured human vascular smooth muscle cells: characterization and physiological significance. Mol Pharmacol 1990;38: 244-252. (Pubitemid 20255311)
45. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994;344:852-854.
46. MacCarthy PA, Grocott-Mason R, Prendergast BD, Shah AM. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ET(A) receptor antagonist. Circulation 2000;101:142-147.
47. Dhein S, Hochreuther S, Aus Dem Spring C et al. Long-term effects of the endothelin(A) receptor antagonist LU 135252 and the angiotensin-converting enzyme inhibitor trandolapril on diabetic angiopathy and nephropathy in a chronic type I diabetes mellitus rat model. J Pharmacol Exp Ther 2000;293:351-359.
48. Verma S, Arikawa E, Lee S et al. Exaggerated coronary reactivity to endothelin-1 in diabetes: reversal with bosentan. Can J Physiol Pharmacol 2002;80:980-986.
49. Katakam P V, Snipes JA, Tulbert CD et al. Impaired endothelin-induced vasoconstriction in coronary arteries of Zucker obese rats is associated with uncoupling of [Ca2+]i signaling. Am J Physiol Regul Integr Comp Physiol 2006;290:R145-R153.
50. Bender SB, Klabunde RE. Altered role of smooth muscle endothelin receptors in coronary endothelin-1 and alpha1-adrenoceptor-mediated vasoconstriction in Type 2 diabetes. Am J Physiol Heart Circ Physiol 2007;293:H2281-H2288.
51. Loesch A. Localisation of endothelin-1 and its receptors in vascular tissue as seen at the electron microscopic level. Curr Vasc Pharmacol 2005;3: 381-392.
52. Anstadt M P, Hutchinson J, Portik-Dobos V et al. Vascular endothelin converting enzyme-1 expression and activity is upregulated in clinical diabetes. Ethn Dis 2002;12:S3-S5.
53. Prior JO, Quiñones MJ, Hernandez-Pampaloni M et al. Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation 2005;111:2291-2298.
54. Kondo I, Mizushige K, Hirao K et al. Ultrasonographic assessment of coronary flow reserve and abdominal fat in obesity. Ultrasound Med Biol 2001;27:1199-1205.
55. Kawata T, Daimon M, Hasegawa R et al. Effect on coronary flow velocity reserve in patients with type 2 diabetes mellitus: comparison between angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist. Am Heart J 2006;151:798.e9-798.15.
56. Schindler TH, Cardenas J, Prior JO et al. Relationship between increasing body weight, insulin resistance, inflammation, adipocytokine leptin, and coronary circulatory function. J Am Coll Cardiol 2006;47:1188-1195.
57. Brame LA, Considine R V, Yamauchi M, Baron AD, Mather KJ. Insulin and endothelin in the acute regulation of adiponectin in vivo in humans. Obes Res 2005;13:582-588.
58. Schindler TH, Facta AD, Prior JO et al. Improvement in coronary vascular dysfunction produced with euglycaemic control in patients with type 2 diabetes. Heart 2007;93:345-349.
59. Wang L, Jerosch-Herold M, Jacobs DR, Shahar E, Folsom AR. Coronary risk factors and myocardial perfusion in asymptomatic adults: the MultiEthnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 2006;47: 565-572. (Pubitemid 43170845)
60. Srinivasan M, Herrero P, McGill JB et al. The effects of plasma insulin and glucose on myocardial blood flow in patients with type 1 diabetes mellitus. J Am Coll Cardiol 2005;46:42-48.
61. Takiuchi S, Rakugi H, Masuyama T et al. Hypertension attenuates the efficacy of hypoglycemic therapy for preserving coronary flow reserve in patients with type 2 diabetes. Hypertens Res 2002;25:893-900.